Tag Archives: small

#437687 Video Friday: Bittle Is a Palm-Sized ...

Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here's what we have so far (send us your events!):

ICRES 2020 – September 28-29, 2020 – Taipei, Taiwan
AUVSI EXPONENTIAL 2020 – October 5-8, 2020 – [Online]
IROS 2020 – October 25-29, 2020 – [Online]
CYBATHLON 2020 – November 13-14, 2020 – [Online]
ICSR 2020 – November 14-16, 2020 – Golden, Colo., USA
Let us know if you have suggestions for next week, and enjoy today's videos.

Rongzhong Li, who is responsible for the adorable robotic cat Nybble, has an updated and even more adorable quadruped that's more robust and agile but only costs around US $200 in kit form on Kickstarter.

Looks like the early bird options are sold out, but a full kit is a $225 pledge, for delivery in December.

[ Kickstarter ]

Thanks Rz!

I still maintain that Stickybot was one of the most elegantly designed robots ever.

[ Stanford ]

With the unpredictable health crisis of COVID-19 continuing to place high demands on hospitals, PAL Robotics have successfully completed testing of their delivery robots in Barcelona hospitals this summer. The TIAGo Delivery and TIAGo Conveyor robots were deployed in Hospital Municipal of Badalona and Hospital Clínic Barcelona following a winning proposal submitted to the European DIH-Hero project. Accerion sensors were integrated onto the TIAGo Delivery Robot and TIAGo Conveyor Robot for use in this project.

[ PAL Robotics ]

Energy Robotics, a leading developer of software solutions for mobile robots used in industrial applications, announced that its remote sensing and inspection solution for Boston Dynamics’s agile mobile robot Spot was successfully deployed at Merck’s thermal exhaust treatment plant at its headquarters in Darmstadt, Germany. Energy Robotics equipped Spot with sensor technology and remote supervision functions to support the inspection mission.

Combining Boston Dynamics’ intuitive controls, robotic intelligence and open interface with Energy Robotics’ control and autonomy software, user interface and encrypted cloud connection, Spot can be taught to autonomously perform a specific inspection round while being supervised remotely from anywhere with internet connectivity. Multiple cameras and industrial sensors enable the robot to find its way around while recording and transmitting information about the facility’s onsite equipment operations.

Spot reads the displays of gauges in its immediate vicinity and can also zoom in on distant objects using an externally-mounted optical zoom lens. In the thermal exhaust treatment facility, for instance, it monitors cooling water levels and notes whether condensation water has accumulated. Outside the facility, Spot monitors pipe bridges for anomalies.

Among the robot’s many abilities, it can detect defects of wires or the temperature of pump components using thermal imaging. The robot was put through its paces on a comprehensive course that tested its ability to handle special challenges such as climbing stairs, scaling embankments and walking over grating.

[ Energy Robotics ]

Thanks Stefan!

Boston Dynamics really should give Dr. Guero an Atlas just to see what he can do with it.

[ DrGuero ]

World's First Socially Distanced Birthday Party: Located in London, the robotic arm was piloted in real time to light the candles on the cake by the founder of Extend Robotics, Chang Liu, who was sat 50 miles away in Reading. Other team members in Manchester and Reading were also able to join in the celebration as the robot was used to accurately light the candles on the birthday cake.

[ Extend Robotics ]

The Robocon in-person competition was canceled this year, but check out Tokyo University's robots in action:

[ Robocon ]

Sphero has managed to pack an entire Sphero into a much smaller sphere.

[ Sphero ]

Squishy Robotics, a small business funded by the National Science Foundation (NSF), is developing mobile sensor robots for use in disaster rescue, remote monitoring, and space exploration. The shape-shifting, mobile, senor robots from UC-Berkeley spin-off Squishy Robotics can be dropped from airplanes or drones and can provide first responders with ground-based situational awareness during fires, hazardous materials (HazMat) release, and natural and man-made disasters.

[ Squishy Robotics ]

Meet Jasper, the small girl with big dreams to FLY. Created by UTS Animal Logic Academy in partnership with the Royal Australian Air Force to encourage girls to soar above the clouds. Jasper was created using a hybrid of traditional animation techniques and technology such as robotics and 3D printing. A KUKA QUANTEC robot is used during the film making to help the Australian Royal Airforce tell their story in a unique way. UTS adapted their High Accurate robot to film consistent paths, creating a video with physical sets and digital characters.

[ AU AF ]

Impressive what the Ghost Robotics V60 can do without any vision sensors on it.

[ Ghost Robotics ]

Is your job moving tiny amounts of liquid around? Would you rather be doing something else? ABB’s YuMi got you.

[ Yumi ]

For his PhD work at the Media Lab, Biomechatronics researcher Roman Stolyarov developed a terrain-adaptive control system for robotic leg prostheses. as a way to help people with amputations feel as able-bodied and mobile as possible, by allowing them to walk seamlessly regardless of the ground terrain.

[ MIT ]

This robot collects data on each cow when she enters to be milked. Milk samples and 3D photos can be taken to monitor the cow’s health status. The Ontario Dairy Research Centre in Elora, Ontario, is leading dairy innovation through education and collaboration. It is a state-of-the-art 175,000 square foot facility for discovery, learning and outreach. This centre is a partnership between the Agricultural Research Institute of Ontario, OMAFRA, the University of Guelph and the Ontario dairy industry.

[ University of Guleph ]

Australia has one of these now, should the rest of us panic?

[ Boeing ]

Daimler and Torc are developing Level 4 automated trucks for the real world. Here is a glimpse into our closed-course testing, routes on public highways in Virginia, and self-driving capabilities development. Our year of collaborating on the future of transportation culminated in the announcement of our new truck testing center in New Mexico.

[ Torc Robotics ] Continue reading

Posted in Human Robots

#437673 Can AI and Automation Deliver a COVID-19 ...

Illustration: Marysia Machulska

Within moments of meeting each other at a conference last year, Nathan Collins and Yann Gaston-Mathé began devising a plan to work together. Gaston-Mathé runs a startup that applies automated software to the design of new drug candidates. Collins leads a team that uses an automated chemistry platform to synthesize new drug candidates.

“There was an obvious synergy between their technology and ours,” recalls Gaston-Mathé, CEO and cofounder of Paris-based Iktos.

In late 2019, the pair launched a project to create a brand-new antiviral drug that would block a specific protein exploited by influenza viruses. Then the COVID-19 pandemic erupted across the world stage, and Gaston-Mathé and Collins learned that the viral culprit, SARS-CoV-2, relied on a protein that was 97 percent similar to their influenza protein. The partners pivoted.

Their companies are just two of hundreds of biotech firms eager to overhaul the drug-discovery process, often with the aid of artificial intelligence (AI) tools. The first set of antiviral drugs to treat COVID-19 will likely come from sifting through existing drugs. Remdesivir, for example, was originally developed to treat Ebola, and it has been shown to speed the recovery of hospitalized COVID-19 patients. But a drug made for one condition often has side effects and limited potency when applied to another. If researchers can produce an ­antiviral that specifically targets SARS-CoV-2, the drug would likely be safer and more effective than a repurposed drug.

There’s one big problem: Traditional drug discovery is far too slow to react to a pandemic. Designing a drug from scratch typically takes three to five years—and that’s before human clinical trials. “Our goal, with the combination of AI and automation, is to reduce that down to six months or less,” says Collins, who is chief strategy officer at SRI Biosciences, a division of the Silicon Valley research nonprofit SRI International. “We want to get this to be very, very fast.”

That sentiment is shared by small biotech firms and big pharmaceutical companies alike, many of which are now ramping up automated technologies backed by supercomputing power to predict, design, and test new antivirals—for this pandemic as well as the next—with unprecedented speed and scope.

“The entire industry is embracing these tools,” says Kara Carter, president of the International Society for Antiviral Research and executive vice president of infectious disease at Evotec, a drug-discovery company in Hamburg. “Not only do we need [new antivirals] to treat the SARS-CoV-2 infection in the population, which is probably here to stay, but we’ll also need them to treat future agents that arrive.”

There are currentlyabout 200 known viruses that infect humans. Although viruses represent less than 14 percent of all known human pathogens, they make up two-thirds of all new human pathogens discovered since 1980.

Antiviral drugs are fundamentally different from vaccines, which teach a person’s immune system to mount a defense against a viral invader, and antibody treatments, which enhance the body’s immune response. By contrast, anti­virals are chemical compounds that directly block a virus after a person has become infected. They do this by binding to specific proteins and preventing them from functioning, so that the virus cannot copy itself or enter or exit a cell.

The SARS-CoV-2 virus has an estimated 25 to 29 proteins, but not all of them are suitable drug targets. Researchers are investigating, among other targets, the virus’s exterior spike protein, which binds to a receptor on a human cell; two scissorlike enzymes, called proteases, that cut up long strings of viral proteins into functional pieces inside the cell; and a polymerase complex that makes the cell churn out copies of the virus’s genetic material, in the form of single-stranded RNA.

But it’s not enough for a drug candidate to simply attach to a target protein. Chemists also consider how tightly the compound binds to its target, whether it binds to other things as well, how quickly it metabolizes in the body, and so on. A drug candidate may have 10 to 20 such objectives. “Very often those objectives can appear to be anticorrelated or contradictory with each other,” says Gaston-Mathé.

Compared with antibiotics, antiviral drug discovery has proceeded at a snail’s pace. Scientists advanced from isolating the first antibacterial molecules in 1910 to developing an arsenal of powerful antibiotics by 1944. By contrast, it took until 1951 for researchers to be able to routinely grow large amounts of virus particles in cells in a dish, a breakthrough that earned the inventors a Nobel Prize in Medicine in 1954.

And the lag between the discovery of a virus and the creation of a treatment can be heartbreaking. According to the World Health Organization, 71 million people worldwide have chronic hepatitis C, a major cause of liver cancer. The virus that causes the infection was discovered in 1989, but effective antiviral drugs didn’t hit the market until 2014.

While many antibiotics work on a range of microbes, most antivirals are highly specific to a single virus—what those in the business call “one bug, one drug.” It takes a detailed understanding of a virus to develop an antiviral against it, says Che Colpitts, a virologist at Queen’s University, in Canada, who works on antivirals against RNA viruses. “When a new virus emerges, like SARS-CoV-2, we’re at a big disadvantage.”

Making drugs to stop viruses is hard for three main reasons. First, viruses are the Spartans of the pathogen world: They’re frugal, brutal, and expert at evading the human immune system. About 20 to 250 nanometers in diameter, viruses rely on just a few parts to operate, hijacking host cells to reproduce and often destroying those cells upon departure. They employ tricks to camouflage their presence from the host’s immune system, including preventing infected cells from sending out molecular distress beacons. “Viruses are really small, so they only have a few components, so there’s not that many drug targets available to start with,” says Colpitts.

Second, viruses replicate quickly, typically doubling in number in hours or days. This constant copying of their genetic material enables viruses to evolve quickly, producing mutations able to sidestep drug effects. The virus that causes AIDS soon develops resistance when exposed to a single drug. That’s why a cocktail of antiviral drugs is used to treat HIV infection.

Finally, unlike bacteria, which can exist independently outside human cells, viruses invade human cells to propagate, so any drug designed to eliminate a virus needs to spare the host cell. A drug that fails to distinguish between a virus and a cell can cause serious side effects. “Discriminating between the two is really quite difficult,” says Evotec’s Carter, who has worked in antiviral drug discovery for over three decades.

And then there’s the money barrier. Developing antivirals is rarely profitable. Health-policy researchers at the London School of Economics recently estimated that the average cost of developing a new drug is US $1 billion, and up to $2.8 billion for cancer and other specialty drugs. Because antivirals are usually taken for only short periods of time or during short outbreaks of disease, companies rarely recoup what they spent developing the drug, much less turn a profit, says Carter.

To change the status quo, drug discovery needs fresh approaches that leverage new technologies, rather than incremental improvements, says Christian Tidona, managing director of BioMed X, an independent research institute in Heidelberg, Germany. “We need breakthroughs.”

Putting Drug Development on Autopilot
Earlier this year, SRI Biosciences and Iktos began collaborating on a way to use artificial intelligence and automated chemistry to rapidly identify new drugs to target the COVID-19 virus. Within four months, they had designed and synthesized a first round of antiviral candidates. Here’s how they’re doing it.

1/5

STEP 1: Iktos’s AI platform uses deep-learning algorithms in an iterative process to come up with new molecular structures likely to bind to and disable a specific coronavirus protein. Illustrations: Chris Philpot

2/5

STEP 2: SRI Biosciences’s SynFini system is a three-part automated chemistry suite for producing new compounds. Starting with a target compound from Iktos, SynRoute uses machine learning to analyze and optimize routes for creating that compound, with results in about 10 seconds. It prioritizes routes based on cost, likelihood of success, and ease of implementation.

3/5

STEP 3: SynJet, an automated inkjet printer platform, tests the routes by printing out tiny quantities of chemical ingredients to see how they react. If the right compound is produced, the platform tests it.

4/5

STEP 4: AutoSyn, an automated tabletop chemical plant, synthesizes milligrams to grams of the desired compound for further testing. Computer-selected “maps” dictate paths through the plant’s modular components.

5/5

STEP 5: The most promising compounds are tested against live virus samples.

Previous
Next

Iktos’s AI platform was created by a medicinal chemist and an AI expert. To tackle SARS-CoV-2, the company used generative models—deep-learning algorithms that generate new data—to “imagine” molecular structures with a good chance of disabling a key coronavirus protein.

For a new drug target, the software proposes and evaluates roughly 1 million compounds, says Gaston-Mathé. It’s an iterative process: At each step, the system generates 100 virtual compounds, which are tested in silico with predictive models to see how closely they meet the objectives. The test results are then used to design the next batch of compounds. “It’s like we have a very, very fast chemist who is designing compounds, testing compounds, getting back the data, then designing another batch of compounds,” he says.

The computer isn’t as smart as a human chemist, Gaston-Mathé notes, but it’s much faster, so it can explore far more of what people in the field call “chemical space”—the set of all possible organic compounds. Unexplored chemical space is huge: Biochemists estimate that there are at least 1063 possible druglike molecules, and that 99.9 percent of all possible small molecules or compounds have never been synthesized.

Still, designing a chemical compound isn’t the hardest part of creating a new drug. After a drug candidate is designed, it must be synthesized, and the highly manual process for synthesizing a new chemical hasn’t changed much in 200 years. It can take days to plan a synthesis process and then months to years to optimize it for manufacture.

That’s why Gaston-Mathé was eager to send Iktos’s AI-generated designs to Collins’s team at SRI Biosciences. With $13.8 million from the Defense Advanced Research Projects Agency, SRI Biosciences spent the last four years automating the synthesis process. The company’s automated suite of three technologies, called SynFini, can produce new chemical compounds in just hours or days, says Collins.

First, machine-learning software devises possible routes for making a desired molecule. Next, an inkjet printer platform tests the routes by printing out and mixing tiny quantities of chemical ingredients to see how they react with one another; if the right compound is produced, the platform runs tests on it. Finally, a tabletop chemical plant synthesizes milligrams to grams of the desired compound.

Less than four months after Iktos and SRI Biosciences announced their collaboration, they had designed and synthesized a first round of antiviral candidates for SARS-CoV-2. Now they’re testing how well the compounds work on actual samples of the virus.

Out of 10
63 possible druglike molecules, 99.9 percent have never been synthesized.

Theirs isn’t the only collaborationapplying new tools to drug discovery. In late March, Alex Zhavoronkov, CEO of Hong Kong–based Insilico Medicine, came across a YouTube video showing three virtual-reality avatars positioning colorful, sticklike fragments in the side of a bulbous blue protein. The three researchers were using VR to explore how compounds might bind to a SARS-CoV-2 enzyme. Zhavoronkov contacted the startup that created the simulation—Nanome, in San Diego—and invited it to examine Insilico’s ­AI-generated molecules in virtual reality.

Insilico runs an AI platform that uses biological data to train deep-learning algorithms, then uses those algorithms to identify molecules with druglike features that will likely bind to a protein target. A four-day training sprint in late January yielded 100 molecules that appear to bind to an important SARS-CoV-2 protease. The company recently began synthesizing some of those molecules for laboratory testing.

Nanome’s VR software, meanwhile, allows researchers to import a molecular structure, then view and manipulate it on the scale of individual atoms. Like human chess players who use computer programs to explore potential moves, chemists can use VR to predict how to make molecules more druglike, says Nanome CEO Steve McCloskey. “The tighter the interface between the human and the computer, the more information goes both ways,” he says.

Zhavoronkov sent data about several of Insilico’s compounds to Nanome, which re-created them in VR. Nanome’s chemist demonstrated chemical tweaks to potentially improve each compound. “It was a very good experience,” says Zhavoronkov.

Meanwhile, in March, Takeda Pharmaceutical Co., of Japan, invited Schrödinger, a New York–based company that develops chemical-simulation software, to join an alliance working on antivirals. Schrödinger’s AI focuses on the physics of how proteins interact with small molecules and one another.

The software sifts through billions of molecules per week to predict a compound’s properties, and it optimizes for multiple desired properties simultaneously, says Karen Akinsanya, chief biomedical scientist and head of discovery R&D at Schrödinger. “There’s a huge sense of urgency here to come up with a potent molecule, but also to come up with molecules that are going to be well tolerated” by the body, she says. Drug developers are seeking compounds that can be broadly used and easily administered, such as an oral drug rather than an intravenous drug, she adds.

Schrödinger evaluated four protein targets and performed virtual screens for two of them, a computing-intensive process. In June, Google Cloud donated the equivalent of 16 million hours of Nvidia GPU time for the company’s calculations. Next, the alliance’s drug companies will synthesize and test the most promising compounds identified by the virtual screens.

Other companies, including Amazon Web Services, IBM, and Intel, as well as several U.S. national labs are also donating time and resources to the Covid-19 High Performance Computing Consortium. The consortium is supporting 87 projects, which now have access to 6.8 million CPU cores, 50,000 GPUs, and 600 petaflops of computational resources.

While advanced technologies could transform early drug discovery, any new drug candidate still has a long road after that. It must be tested in animals, manufactured in large batches for clinical trials, then tested in a series of trials that, for antivirals, lasts an average of seven years.

In May, the BioMed X Institute in Germany launched a five-year project to build a Rapid Antiviral Response Platform, which would speed drug discovery all the way through manufacturing for clinical trials. The €40 million ($47 million) project, backed by drug companies, will identify ­outside-the-box proposals from young scientists, then provide space and funding to develop their ideas.

“We’ll focus on technologies that allow us to go from identification of a new virus to 10,000 doses of a novel potential therapeutic ready for trials in less than six months,” says BioMed X’s Tidona, who leads the project.

While a vaccine will likely arrive long before a bespoke antiviral does, experts expect COVID-19 to be with us for a long time, so the effort to develop a direct-acting, potent antiviral continues. Plus, having new antivirals—and tools to rapidly create more—can only help us prepare for the next pandemic, whether it comes next month or in another 102 years.

“We’ve got to start thinking differently about how to be more responsive to these kinds of threats,” says Collins. “It’s pushing us out of our comfort zones.”

This article appears in the October 2020 print issue as “Automating Antivirals.” Continue reading

Posted in Human Robots

#437671 Video Friday: Researchers 3D Print ...

Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here’s what we have so far (send us your events!):

ICRES 2020 – September 28-29, 2020 – Taipei, Taiwan
AUVSI EXPONENTIAL 2020 – October 5-8, 2020 – [Online]
IROS 2020 – October 25-29, 2020 – [Online]
ROS World 2020 – November 12, 2020 – [Online]
CYBATHLON 2020 – November 13-14, 2020 – [Online]
ICSR 2020 – November 14-16, 2020 – Golden, Colo., USA
Let us know if you have suggestions for next week, and enjoy today’s videos.

The Giant Gundam in Yokohama is actually way cooler than I thought it was going to be.

[ Gundam Factory ] via [ YouTube ]

A new 3D-printing method will make it easier to manufacture and control the shape of soft robots, artificial muscles and wearable devices. Researchers at UC San Diego show that by controlling the printing temperature of liquid crystal elastomer, or LCE, they can control the material’s degree of stiffness and ability to contract—also known as degree of actuation. What’s more, they are able to change the stiffness of different areas in the same material by exposing it to heat.

[ UCSD ]

Thanks Ioana!

This is the first successful reactive stepping test on our new torque-controlled biped robot named Bolt. The robot has 3 active degrees of freedom per leg and one passive joint in ankle. Since there is no active joint in ankle, the robot only relies on step location and timing adaptation to stabilize its motion. Not only can the robot perform stepping without active ankles, but it is also capable of rejecting external disturbances as we showed in this video.

[ ODRI ]

The curling robot “Curly” is the first AI-based robot to demonstrate competitive curling skills in an icy real environment with its high uncertainties. Scientists from seven different Korean research institutions including Prof. Klaus-Robert Müller, head of the machine-learning group at TU Berlin and guest professor at Korea University, have developed an AI-based curling robot.

[ TU Berlin ]

MoonRanger, a small robotic rover being developed by Carnegie Mellon University and its spinoff Astrobotic, has completed its preliminary design review in preparation for a 2022 mission to search for signs of water at the moon’s south pole. Red Whittaker explains why the new MoonRanger Lunar Explorer design is innovative and different from prior planetary rovers.

[ CMU ]

Cobalt’s security robot can now navigate unmodified elevators, which is an impressive feat.

Also, EXTERMINATE!

[ Cobalt ]

OrionStar, the robotics company invested in by Cheetah Mobile, announced the Robotic Coffee Master. Incorporating 3,000 hours of AI learning, 30,000 hours of robotic arm testing and machine vision training, the Robotic Coffee Master can perform complex brewing techniques, such as curves and spirals, with millimeter-level stability and accuracy (reset error ≤ 0.1mm).

[ Cheetah Mobile ]

DARPA OFFensive Swarm-Enabled Tactics (OFFSET) researchers recently tested swarms of autonomous air and ground vehicles at the Leschi Town Combined Arms Collective Training Facility (CACTF), located at Joint Base Lewis-McChord (JBLM) in Washington. The Leschi Town field experiment is the fourth of six planned experiments for the OFFSET program, which seeks to develop large-scale teams of collaborative autonomous systems capable of supporting ground forces operating in urban environments.

[ DARPA ]

Here are some highlights from Team Explorer’s SubT Urban competition back in February.

[ Team Explorer ]

Researchers with the Skoltech Intelligent Space Robotics Laboratory have developed a system that allows easy interaction with a micro-quadcopter with LEDs that can be used for light-painting. The researchers used a 92x92x29 mm Crazyflie 2.0 quadrotor that weighs just 27 grams, equipped with a light reflector and an array of controllable RGB LEDs. The control system consists of a glove equipped with an inertial measurement unit (IMU; an electronic device that tracks the movement of a user’s hand), and a base station that runs a machine learning algorithm.

[ Skoltech ]

“DeKonBot” is the prototype of a cleaning and disinfection robot for potentially contaminated surfaces in buildings such as door handles, light switches or elevator buttons. While other cleaning robots often spray the cleaning agents over a large area, DeKonBot autonomously identifies the surface to be cleaned.

[ Fraunhofer IPA ]

On Oct. 20, the OSIRIS-REx mission will perform the first attempt of its Touch-And-Go (TAG) sample collection event. Not only will the spacecraft navigate to the surface using innovative navigation techniques, but it could also collect the largest sample since the Apollo missions.

[ NASA ]

With all the robotics research that seems to happen in places where snow is more of an occasional novelty or annoyance, it’s good to see NORLAB taking things more seriously

[ NORLAB ]

Telexistence’s Model-T robot works very slowly, but very safely, restocking shelves.

[ Telexistence ] via [ YouTube ]

Roboy 3.0 will be unveiled next month!

[ Roboy ]

KUKA ready2_educate is your training cell for hands-on education in robotics. It is especially aimed at schools, universities and company training facilities. The training cell is a complete starter package and your perfect partner for entry into robotics.

[ KUKA ]

A UPenn GRASP Lab Special Seminar on Data Driven Perception for Autonomy, presented by Dapo Afolabi from UC Berkeley.

Perception systems form a crucial part of autonomous and artificial intelligence systems since they convert data about the relationship between an autonomous system and its environment into meaningful information. Perception systems can be difficult to build since they may involve modeling complex physical systems or other autonomous agents. In such scenarios, data driven models may be used to augment physics based models for perception. In this talk, I will present work making use of data driven models for perception tasks, highlighting the benefit of such approaches for autonomous systems.

[ GRASP Lab ]

A Maryland Robotics Center Special Robotics Seminar on Underwater Autonomy, presented by Ioannis Rekleitis from the University of South Carolina.

This talk presents an overview of algorithmic problems related to marine robotics, with a particular focus on increasing the autonomy of robotic systems in challenging environments. I will talk about vision-based state estimation and mapping of underwater caves. An application of monitoring coral reefs is going to be discussed. I will also talk about several vehicles used at the University of South Carolina such as drifters, underwater, and surface vehicles. In addition, a short overview of the current projects will be discussed. The work that I will present has a strong algorithmic flavour, while it is validated in real hardware. Experimental results from several testing campaigns will be presented.

[ MRC ]

This week’s CMU RI Seminar comes from Scott Niekum at UT Austin, on Scaling Probabilistically Safe Learning to Robotics.

Before learning robots can be deployed in the real world, it is critical that probabilistic guarantees can be made about the safety and performance of such systems. This talk focuses on new developments in three key areas for scaling safe learning to robotics: (1) a theory of safe imitation learning; (2) scalable reward inference in the absence of models; (3) efficient off-policy policy evaluation. The proposed algorithms offer a blend of safety and practicality, making a significant step towards safe robot learning with modest amounts of real-world data.

[ CMU RI ] Continue reading

Posted in Human Robots

#437643 Video Friday: Matternet Launches Urban ...

Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here's what we have so far (send us your events!):

IROS 2020 – October 25-25, 2020 – [Online]
Bay Area Robotics Symposium – November 20, 2020 – [Online]
ACRA 2020 – December 8-10, 2020 – [Online]
Let us know if you have suggestions for next week, and enjoy today's videos.

Sixteen teams chose their roster of virtual robots and sensor payloads, some based on real-life subterranean robots, and submitted autonomy and mapping algorithms that SubT Challenge officials then tested across eight cave courses in the cloud-based SubT Simulator. Their robots traversed the cave environments autonomously, without any input or adjustments from human operators. The Cave Circuit Virtual Competition teams earned points by correctly finding, identifying, and localizing up to 20 artifacts hidden in the cave courses within five-meter accuracy.

[ SubT ]

This year, the KUKA Innovation Award’s international jury of experts received a total of more than 40 ideas. The five finalist teams had time until November to implement their ideas. A KUKA LBR Med lightweight robot – the first robotic component to be certified for integration into a medical device – has been made available to them for this purpose. Beyond this, the teams have received a training for the hardware and coaching from KUKA experts throughout the competition. At virtual.MEDICA from 16-19.11.2020, the finalists presented their concepts to an international audience of experts and to the Innovation Award jury.

The winner of the KUKA Innovation Award 2020, worth 20,000 euros, is Team HIFUSK from the Scuola Superiore Sant'Anna in Italy.

[ KUKA Innovation Award ]

Like everything else the in-person Cybathlon event was cancelled, but the competition itself took place, just a little more distributed than it would have been otherwise.

[ Cybathlon ]

Matternet, developer of the world's leading urban drone logistics platform, today announced the launch of operations at Labor Berlin Charité Vivantes in Germany. The program kicked-off November 17, 2020 with permanent operations expected to take flight next year, creating the first urban BVLOS [Beyond Visual Line of Sight] medical drone delivery network in the European Union. The drone network expects to significantly improve the timeliness and efficiency of Labor Berlin’s diagnostics services by providing an option to avoid roadway delays, which will improve patient experience with potentially life-saving benefits and lower costs.

Routine BVLOS over an urban area? Impressive.

[ Matternet ]

Robots playing diabolo!

Thanks Thilo!

[ OMRON Sinic X]

Anki's tech has been repackaged into this robot that serves butter:

[ Butter Robot ]

Berkshire Grey just announced our Picking With Purpose Program in which we’ve partnered our robotic automation solutions with food rescue organizations City Harvest and The Greater Boston Food Bank to pick, pack, and distribute food to families in need in time for Thanksgiving. Berkshire Grey donated about 40,000 pounds of food, used one of our robotic automation systems to pick and pack that food into meal boxes for families in need, and our team members volunteered to run the system. City Harvest and The Greater Boston Food Bank are distributing the 4,000 meal boxes we produced. This is just the beginning. We are building a sponsorship program to make Picking With Purpose an ongoing initiative.

[ Berkshire Grey ]

Thanks Peter!

We posted a video previously of Cassie learning to skip, but here's a much more detailed look (accompanying an ICRA submission) that includes some very impressive stair descending.

[ DRL ]

From garage inventors to university students and entrepreneurs, NASA is looking for ideas on how to excavate the Moon’s icy regolith, or dirt, and deliver it to a hypothetical processing plant at the lunar South Pole. The NASA Break the Ice Lunar Challenge, a NASA Centennial Challenge, is now open for registration. The competition will take place over two phases and will reward new ideas and approaches for a system architecture capable of excavating and moving icy regolith and water on the lunar surface.

[ NASA ]

Adaptation to various scene configurations and object properties, stability and dexterity in robotic grasping manipulation is far from explored. This work presents an origami-based shape morphing fingertip design to actively tackle the grasping stability and dexterity problems. The proposed fingertip utilizes origami as its skeleton providing degrees of freedom at desired positions and motor-driven four-bar-linkages as its transmission components to achieve a compact size of the fingertip.

[ Paper ]

“If Roboy crashes… you die.”

[ Roboy ]

Traditionally lunar landers, as well as other large space exploration vehicles, are powered by solar arrays or small nuclear reactors. Rovers and small robots, however, are not big enough to carry their own dedicated power supplies and must be tethered to their larger counterparts via electrical cables. Tethering severely restricts mobility, and cables are prone to failure due to lunar dust (regolith) interfering with electrical contact points. Additionally, as robots become smaller and more complex, they are fitted with additional sensors that require more power, further exacerbating the problem. Lastly, solar arrays are not viable for charging during the lunar night. WiBotic is developing rapid charging systems and energy monitoring base stations for lunar robots, including the CubeRover – a shoebox-sized robot designed by Astrobotic – that will operate autonomously and charge wirelessly on the Moon.

[ WiBotic ]

Watching pick and place robots is my therapy.

[ Soft Robotics ]

It's really, really hard to beat liquid fuel for energy storage, as Quaternium demonstrates with their hybrid drone.

[ Quaternium ]

Thanks Gregorio!

State-of-the-art quadrotor simulators have a rigid and highly-specialized structure: either are they really fast, physically accurate, or photo-realistic. In this work, we propose a novel quadrotor simulator: Flightmare.

[ Flightmare ]

Drones that chuck fire-fighting balls into burning buildings, sure!

[ LARICS ]

If you missed ROS World, that's okay, because all of the talks are now online. Here's the opening keynote from Vivian Chu and Diligent robotics, along with a couple fun lightning talks.

[ ROS World 2020 ]

This week's CMU RI Seminar is by Chelsea Finn from Stanford University, on Data Scalability for Robot Learning.

Recent progress in robot learning has demonstrated how robots can acquire complex manipulation skills from perceptual inputs through trial and error, particularly with the use of deep neural networks. Despite these successes, the generalization and versatility of robots across environment conditions, tasks, and objects remains a major challenge. And, unfortunately, our existing algorithms and training set-ups are not prepared to tackle such challenges, which demand large and diverse sets of tasks and experiences. In this talk, I will discuss two central challenges that pertain to data scalability: first, acquiring large datasets of diverse and useful interactions with the world, and second, developing algorithms that can learn from such datasets. Then, I will describe multiple approaches that we might take to rethink our algorithms and data pipelines to serve these goals. This will include algorithms that allow a real robot to explore its environment in a targeted manner with minimal supervision, approaches that can perform robot reinforcement learning with videos of human trial-and-error experience, and visual model-based RL approaches that are not bottlenecked by their capacity to model everything about the world.

[ CMU RI ] Continue reading

Posted in Human Robots

#437639 Boston Dynamics’ Spot Is Helping ...

In terms of places where you absolutely want a robot to go instead of you, what remains of the utterly destroyed Chernobyl Reactor 4 should be very near the top of your list. The reactor, which suffered a catastrophic meltdown in 1986, has been covered up in almost every way possible in an effort to keep its nuclear core contained. But eventually, that nuclear material is going to have to be dealt with somehow, and in order to do that, it’s important to understand which bits of it are just really bad, and which bits are the actual worst. And this is where Spot is stepping in to help.

The big open space that Spot is walking through is right next to what’s left of Reactor 4. Within six months of the disaster, Reactor 4 was covered in a sarcophagus made of concrete and steel to try and keep all the nasty nuclear fuel from leaking out more than it already had, and it still contains “30 tons of highly contaminated dust, 16 tons of uranium and plutonium, and 200 tons of radioactive lava.” Oof. Over the next 10 years, the sarcophagus slowly deteriorated, and despite the addition of that gigantic network of steel support beams that you can see in the video, in the late 1990s it was decided to erect an enormous building over the entire mess to try and stabilize it for as long as possible.

Reactor 4 is now snugly inside the massive New Safe Confinement (NSC) structure, and the idea is that eventually, the structure will allow for the safe disassembly of what’s left of the reactor, although nobody is quite sure how to do that. This is all just to say that the area inside of the containment structure offers a lot of good opportunities for robots to take over from humans.

This particular Spot is owned by the U.K. Atomic Energy Authority, and was packed off to Russia with the assistance of the Robotics and Artificial Intelligence in Nuclear (RAIN) initiative and the National Centre for Nuclear Robotics. Dr. Dave Megson-Smith, who is a researcher at the University of Bristol, in the U.K., and part of the Hot Robotics Facility at the National Nuclear User Facility, was one of the scientists lucky enough to accompany Spot on its adventure. Megson-Smith specializes in sensor development, and he equipped Spot with a collimated radiation sensor in addition to its mapping payload. “We actually built a map of the radiation coming out of the front wall of Chernobyl power plant as we were in there with it,” Megson-Smith told us, and was able to share this picture, which shows a map of gamma photon count rate:

Image: University of Bristol

Researchers equipped Spot with a collimated radiation sensor and use one of the data readings (gamma photon count rate) to create a map of the radiation coming out of the front wall of the Chernobyl power plant.

So what’s the reason you’d want to use a very expensive legged robot to wander around what looks like a very flat and robot friendly floor? As it turns out, the floor is very dusty in there, and a priority inside the NSC is to keep dust down as much as possible, since the dust is radioactive and gets on everything and is consequently the easiest way for radioactivity to escape the NSC. “You want to minimize picking up material, so we consider the total contact surface area,” says Megson-Smith. “If you use a legged system rather than a wheeled or tracked system, you have a much smaller footprint and you disturb the environment a lot less.” While it’s nice that Spot is nimble and can climb stairs and stuff, tracked vehicles can do that as well, so in this case, the primary driving factor of choosing a robot to work inside Chernobyl is minimizing those contact points.

Right now, routine weekly measurements in contaminated spaces at Chernobyl are done by humans, which puts those humans at risk. Spot, or a robot like it, could potentially take over from those humans, as a sort of “automated safety checker”

Right now, routine weekly measurements in contaminated spaces at Chernobyl are done by humans, which puts those humans at risk. Spot, or a robot like it, could potentially take over from those humans, as a sort of “automated safety checker” able to work in medium level contaminated environments.” As far as more dangerous areas go, there’s a lot of uncertainty about what Spot is actually capable of, according to Megson-Smith. “What you think the problems are, and what the industry thinks the problems are, are subtly different things.

We were thinking that we’d have to make robots incredibly radiation proof to go into these contaminated environments, but they said, “can you just give us a system that we can send into places where humans already can go, but where we just don’t want to send humans.” Making robots incredibly radiation proof is challenging, and without extensive testing and ruggedizing, failures can be frequent, as many robots discovered at Fukushima. Indeed, Megson-Smith that in Fukushima there’s a particular section that’s known as a “robot graveyard” where robots just go to die, and they’ve had to up their standards again and again to keep the robots from failing. “So the thing they’re worried about with Spot is, what is its tolerance? What components will fail, and what can we do to harden it?” he says. “We’re approaching Boston Dynamics at the moment to see if they’ll work with us to address some of those questions.

There’s been a small amount of testing of how robots fair under harsh radiation, Megson-Smith told us, including (relatively recently) a KUKA LBR800 arm, which “stopped operating after a large radiation dose of 164.55(±1.09) Gy to its end effector, and the component causing the failure was an optical encoder.” And in case you’re wondering how much radiation that is, a 1 to 2 Gy dose to the entire body gets you acute radiation sickness and possibly death, while 8 Gy is usually just straight-up death. The goal here is not to kill robots (I mean, it sort of is), but as Megson-Smith says, “if we can work out what the weak points are in a robotic system, can we address those, can we redesign those, or at least understand when they might start to fail?” Now all he has to do is convince Boston Dynamics to send them a Spot that they can zap until it keels over.

The goal for Spot in the short term is fully autonomous radiation mapping, which seems very possible. It’ll also get tested with a wider range of sensor packages, and (happily for the robot) this will all take place safely back at home in the U.K. As far as Chernobyl is concerned, robots will likely have a substantial role to play in the near future. “Ultimately, Chernobyl has to be taken apart and decommissioned. That’s the long-term plan for the facility. To do that, you first need to understand everything, which is where we come in with our sensor systems and robotic platforms,” Megson-Smith tells us. “Since there are entire swathes of the Chernobyl nuclear plant where people can’t go in, we’d need robots like Spot to do those environmental characterizations.” Continue reading

Posted in Human Robots